UGT1A1 rs887829 TT (Gilbert syndrome) reduces bilirubin glucuronidation and causes isolated unconjugated hyperbilirubinemia.

The claim that reduced-function $UGT1A1$ variants, specifically rs887829 TT associated with Gilbert syndrome, lead to impaired bilirubin glucuronidation and elevated unconjugated total bilirubin with normal liver enzymes is strongly supported by scientific evidence.

Clinical and effectiveness evidence

Large-scale genomic studies, including data from the UK Biobank, consistently demonstrate that the rs887829 TT genotype is a primary driver of serum bilirubin levels, explaining approximately 25–40% of population variance ($p < 5 \times 10^{-8}$). Clinical observations confirm that individuals with these variants typically exhibit total bilirubin levels between 1 and 6 mg/dL, primarily in the unconjugated form. A critical diagnostic hallmark of Gilbert syndrome is the presence of these elevated levels in the absence of other liver pathologies, meaning liver enzymes such as Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) remain within normal reference ranges.

Mechanistic explanations

The mechanism is rooted in the genetic regulation of the $UGT1A1$ enzyme:

• Genetic Linkage: While rs887829 is an intronic variant, it serves as a highly reliable proxy ($r^2 \approx 1.0$) for the $UGT1A128$ (TA7) and $UGT1A137$ (TA8) promoter expansions. These expansions directly interfere with the binding of transcription factors, leading to reduced mRNA expression and lower enzyme production in hepatocytes.
• Metabolic Impairment: $UGT1A1$ is the sole enzyme responsible for glucuronidation—the process of attaching glucuronic acid to bilirubin to make it water-soluble. Reduced enzyme activity limits this conjugation step, causing water-insoluble unconjugated bilirubin to accumulate systemically.
• Hepatocellular Integrity: Because this genetic variant specifically affects the metabolic capacity for conjugation rather than causing cellular necrosis or inflammation, there is no leakage of intracellular enzymes. Consequently, AST and ALT—markers of hepatocyte damage—remain stable and normal.

Bottom line

The rs887829 TT variant reliably identifies a specific metabolic deficit in bilirubin conjugation. This leads to the isolated unconjugated hyperbilirubinemia characteristic of Gilbert syndrome, which is clinically distinguished from liver disease by the absence of elevated AST and ALT levels.